Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH). The study aims to evaluate the effectiveness and safety of two experimental drugs, REGN9933 and REGN7508, in preventing venous thromboembolism (VTE) in adults with a peripherally inserted central catheter (PICC).
Intervention/Treatment: The interventions being tested are REGN9933 and REGN7508, both monoclonal antibodies administered intravenously. These drugs are designed to prevent blood clots in patients with PICC lines by targeting Factor XI.
Study Design: This is a randomized, double-blind, placebo-controlled study with a parallel intervention model. Participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on March 1, 2024, with the latest update submitted on August 28, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
Market Implications: The study’s progress could significantly impact Regeneron’s stock performance and investor sentiment, especially if the results demonstrate efficacy and safety. Success in this study could position Regeneron favorably against competitors in the anticoagulant market, potentially leading to increased market share.
The study is currently ongoing, with further details available on the ClinicalTrials portal.